MedTrace Logo

Repeated Neurocognitive Measurements in Depressed Patients

NCT05991232 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2026-02-25

No results posted yet for this study

Summary

In this project, we will A) track the functioning of a collection of potential neurobiological targets for depression over time, B) examine how fluctuations in the functioning of those targets relates to real-world functioning, and C) in a subset of the sample, determine how the functioning in those targets is altered by a single dose of ketamine.

Conditions

  • Depression, Unipolar

Interventions

DRUG

Intravenous Ketamine

Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Sponsors & Collaborators

  • Jay Fournier

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2028-04-30
Completion
2029-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05991232 on ClinicalTrials.gov